nd quarter of 2011 compared to $10.7 million in the first quarter. The decrease was due to lower generic development costs. Selling, general and administrative expenses for the second quarter 2011 decreased to $46.2 million compared to $46.9 million in the first quarter of 2011. The decrease reflects lower employment costs.
Cash and cash equivalents and marketable securitiesThe aggregate balance as of June 30, 2011 was approximately $346 million.
Product and Pipeline UpdateIn July, Strativa Pharmaceuticals returned the U.S. commercialization rights of Zuplenz® to its development partner, MonoSol Rx, as part of the branded division's restructuring announced in June.
In July, the Company received a notice letter from a generic pharmaceutical manufacturer, advising that it has filed an Abbreviated New Drug Application with the U.S. FDA containing a Paragraph IV certification referencing Megace® ES. Megace® ES is protected by Elan Pharma International Limited's U.S. Patents 6,592,903 and 7,101,576. The Company intends, with Elan, to investigate the Paragraph IV certification and ANDA, and to enforce its patents, which expire in 2020 and 2024, respectively, as appropriate.
Par Pharmaceutical, along with third-party partners, currently has approximately 31 ANDAs pending with the FDA, 13 of which it believes to be first-to-file opportunities.
Conference CallAccess to the live webcast can be made via the Company's website at www.parpharm.com.
55151925A replay of the conference call will be available for two weeks approximately one hour after the call.
90475213Non-GAAP MeasuresPar Pharma
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1
|SOURCE Par Pharmaceutical Companies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?2
. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 20113
. Avanir Pharmaceuticals to Present at Two Investor Conferences in August4
. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society5
. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®6
. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters7
. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer8
. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 99
. BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production10
. Though Essential to Pharmaceutical Sales Success, the Use of Health Outcomes Data Often Overlooked by Sales Leaders11
. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update